. 1997. Leishmania major: Molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. Experimental Parasitology 87, 212-221. The crystal structures of papain, cruzain, and human liver cathepsin B were used to build homology-based enzyme models of a cathepsin L-like cysteine protease (cpL) and a cathepsin B-like cysteine protease (cpB) from the protozoan parasite Leishmania major. Although structurally a member of the cathepsin B subfamily, the L. major cpB is not able to cleave synthetic substrates having an arginine in position P 2 . This biochemical property correlates with the prediction of a glycine instead of a glutamic acid at position 205 (papain numbering). The modeled active sites of the L. major cpB and cpL were used to screen the Available Chemicals Directory (a database of about 150,000 commercially available compounds) for potential cysteine protease inhibitors, using DOCK3.5. Based on both steric and force field considerations, 69 compounds were selected. Of these, 18 showed IC 50 's between 50 and 100 M and 3 had IC 50 's below 50 M. A secondary library of compounds, originally derived from a structural screen against the homologous protease of Plasmodium falciparum (falcipain), and subsequently expanded by combinatorial chemistry, was also screened. Three inhibitors were identified which were not only effective against the L. major protease but also inhibited parasite growth at 5-50 M.
INTRODUCTION
Parasitic diseases are major worldwide health problems now exacerbated by the emergence of drug-resistant organisms (Moran and Bernard 1989) . Leishmaniasis, a spectrum of diseases produced by protozoan parasites of the genus Leishmania, affects more than 12 million people. Current therapy for leishmaniasis is suboptimal due to toxicity of available therapeutic agents and the emergence of drug resistance (Grogl et al. 1992) . Compounding these problems is the fact that many countries and regions where the disease is endemic are economically poor. As a result, major pharmaceutical companies have historically had little interest in anti-leishmanial drug development.
To facilitate the cost-effective development of new antiparasitic chemotherapy, we have been exploring the application of structurebased drug design, utilizing computational screens of available chemical databases as an inexpensive shortcut to identify potential chemotherapeutic leads. One appealing target in the Leishmania parasites is a family of cysteine proteases required for parasite replication and virulence (Coombs and Baxter 1984; McKerrow et al. 1993; Sakanari et al. 1995; Mottram et al. 1996) . Because of the relationship of these target enzymes to cysteine proteases of known structure and catalytic mechanism, it is feasible to utilize molecular modeling techniques to visualize the active site of the enzyme and computationally design or screen for inhibitors. While molecular modeling is not a substitute for crystallographic structure determination, it has proven useful in identifying or designing inhibitors for two other parasitic infections, schistosomiasis and malaria (Ring et al. 1993) . The Leishmania cysteine proteases present a similar opportunity in that there are sufficient data from structural analysis of closely related enzymes to allow a reasonable and useful model to be built.
In this initial work, we have produced structural models of the two major cysteine proteases of L. major, a cathepsin L-like cysteine protease (cpL) and a cathepsin B-like cysteine protease (cpB). These models were used to develop hypotheses on the structural basis of substrate specificity. The predicted active site binding regions of both the L. major cpL and cpB were then used to screen a public domain database of small molecular weight compounds for potential chemotherapeutic leads. In addition a library of compounds derived from a lead found by a similar approach using the homologous malaria cysteine protease as a target (Ring et al. 1993; Li et al. 1994 Li et al. , 1995 Li et al. , 1996 was also screened. Because reagent quantities of the L. major cpB were available it was used for confirmatory screens of DOCK3.5-derived leads. The most promising compounds were investigated both for their ability to inhibit parasite growth and for any toxicity against host cells.
MATERIALS AND METHODS

Homology Modeling and Docking of Inhibitors
The mature protein sequences of L. major cpL (216 aa, GenBank locus U43706) and L. major cpB (243 aa, GenBank locus 43705) (Sakanari et al. 1997) were used to search the Brookhaven Protein Databank of threedimensional structures (Bernstein et al. 1978) . Both sequences show high homology with the papain family proteases. Based on the crystal structures of papain (Kamphuis et al. 1984) , cruzain (McGrath et al. 1995) , and human liver cathepsin B (Musil et al. 1991) homology-based enzyme models were built (Fig. 1) using the programs InsightII (Biosym Technologies, San Diego, CA) and Midas Plus (Computer Graphics Laboratory, University of California San Francisco) (Ferrin et al. 1988; Huang et al. 1991) (http://www.cgl.ucsf.edu/midasplus.html). For L. major cpL the crystal structures of cruzain and papain (59 and 41% sequence identity, respectively) were used, whereas for L. major cpB, the three-dimensional structure of human liver cathepsin B served as reference protein (54% sequence identity). Identities in the structural conserved regions (SCR) and especially within the active site cleft of the enzymes reached values of up to 80%. Comparing known crystal structures with models built by homology, modeling revealed that sequence identities higher than 70% lead to highly accurate structural predictions (Mosimann et al. 1995) .
In order to find structurally conserved regions, sequences of the reference proteins were manually aligned based on their secondary structure. The sequence of the corresponding parasite protease was then aligned to the reference proteases and the coordinates were assigned within the SCR regions. Loops or variable regions (VR), which are located between SCRs, were found exclusively at the surface of the proteases, not interacting with the active site. Coordinates for the VRs were either directly generated or assigned from known crystal structures. The conformation of side chains were retained in conserved positions and the statistically most likely rotamer (rotational position of side chain based on analysis of all known protein structures containing that amino acid) was chosen when no conformational information was available. The final structures were refined by energy minimization using the AMBER potential function. The quality of the models was validated with QPACK (Gregoret and Cohen 1990), VADAR (University of Alberta, Protein Engineering Network of Centres of Excellence), and the 3D profile method (Luthy et al. 1992) .
All color figures shown are generated using Midas Plus. Primary sequence alignments were performed using the software package GCG (Genetics Computer Group Inc., Madison, WI). Three-dimensional structures of inhibitors were generated with Sybyl and the CONCORD algorithm (Tripos Inc., St. Louis, MO). Partial charges were calculated using the Gasteiger-Masili method within Sybyl. Searching the Available Chemicals Directory (ACD) for potential protease inhibitor leads was carried out using DOCK3.5 in SEARCH mode (contact and force field scores). Compounds of high interest were ''redocked'' using the SINGLE mode function. (For further details of the DOCK approach and the program see Kuntz 1992; Kuntz et al. 1994 ; and http://www.cmpharm.ucsf.edu/kuntz/dock.html). All computer-assisted modeling and docking was performed on Silicon Graphics Workstation (IRIS4D/35 or Indigo2).
Enzyme Assays
The native L. major cpB was a generous gift of Dr. Jacques Bouvier (Ciba-Geigy, CH-1566 St. Aubin, Switzerland). Its purity was confirmed by silver-stained SDS-PAGE. Papain [EC 3.4.22 .2] and mammalian cathepsin B (bovine spleen) [EC 3.4.22 .1] were purchased from Sigma. Recombinant cruzain was produced as previously described (Eakin et al. 1992 (Eakin et al. , 1993 .
All proteases were assayed at 25°C using an automated microtiter plate spectrofluorometer (Labsystem Fluoroscan II). Activity was detected by the liberation of 7-amino-4-methyl coumarin (AMC) (Knight 1995a) (excitation wavelength ‫ס‬ 355 nm and emission wavelength ‫ס‬ 460 nm) from the synthetic peptide substrate Z-Phe-Arg-AMC or Z-Arg-Arg-AMC (Z ‫ס‬ benzoyloxycarbonyl; Phe ‫ס‬ phenylalanine; Arg ‫ס‬ arginine) (Enzyme Systems Products, Livermore, CA). The enzyme concentrations were determined by active site titration (Barrett et al. 1982; Knight 1995b) . Inhibitors (20-mM stock solutions, dissolved in dimethyl sulfoxide (DMSO), stored at −20°C) at various concentrations were preincubated with the respective enzyme for 5 min before the reaction was started by adding the substrate. Enzyme activities were expressed as a percentage of residual activity compared to an uninhibited control and plotted versus increasing inhibitor concentrations in order to calculate the IC 50 values.
Assay Conditions
L. major cpB. 100 mM Na acetate, pH 5.5, 10 mM dithiothreitol (DTT), 1 mM EDTA, 0.1% Triton X-100, 50
Papain and mammalian Cathepsin B. 100 mM Na acetate, pH 5.5, 10 mM DTT, 100 M Z-Phe-Arg-AMC final concentration, K m ‫ס‬ 50 and 110 M, respectively.
Cruzain. The assay conditions were the same as for papain except the substrate concentration was 20 M, K m ‫ס‬ 1 M. K m values were determined by nonlinear regression using the software Ultrafit (Biosoft Inc., Ferguson, MO).
Cell Culture
L. major promastigotes LV39(MRHO/SU/59/P) were grown at 27°C in RPMI-1640 containing 10% (v/v) heatinactivated fetal bovine serum and 20% Brain Heart Infusion Tryptose. Cell growth was determined by counting the parasites with a neubauer hemocytometer. Inhibitors dissolved in DMSO were added from a 20-mM stock solution. DMSO concentrations up to 0.5% showed no effect on the parasite.
RESULTS AND DISCUSSION
The structure of the active site clefts of cysteine proteases from the papain family are highly conserved. The cleavage site or catalytic triad of all cysteine proteases consists of a nucleophilic cysteine, a histidine, and an asparagine. However, the S-subsites show striking differences (Table I ). These sites are responsible for the substrate specificity (Schechter and Berger 1967; Barrett and Kirschke 1981; Menard 1994, 1996) . The SЈ-subsites, while conserved, show an obvious difference in cpLs and cpBs. Cathepsin B-like proteases have an occluding loop which contains the two histidines (His110 and His111 in cathepsin B human liver; His101 and His 102 in L. major cpB, shown in Table I ) that are required for the exopeptidase activity (dipeptidyl carboxypeptidase activity) of cathepsin B (Aronson and Barrett 1978; Turk et al. 1995; Illy et al. 1997) . The polypeptide chain of cysteine proteases from the papain family is folded into two domains, between which the V-shaped active-site cleft is formed (Musil et al. 1991) . Although the interdomain interface has a similar shape in papain and in cathepsin B, the amino acid residues involved are different. Specific residues of the Note. Key residues of the active site clefts of papain family cysteine proteases are shown. The top three proteases served as reference proteins to build the homology models of the two Leishmania proteases. The catalytic triad and the SЈ subsites are highly conserved whereas the S subsites show differences responsible for differences in substrate specificity. Note the two histidines in the S 2 Ј subsite, appearing only in cathepsin B and L. major cpB.
domain interface of human liver cathepsin B are Glu36, Ser39, Glu171, Arg202, and Ala218 (Musil et al. 1991) . The occluding loop and the interface residues are structural features of members of the cathepsin B subfamily. An occluding loop with the two histidines appears in L. major cpB and the residues within the interface are identical to human liver cathepsin B with only one minor exchange of Arg202 to Lys. With these structural features the L. major cpB is clearly a member of the cathepsin B subfamily. Consistent with this conclusion is the fact that the primary sequence of L. major cpB has high overall identity (54%) to human liver cathepsin B but a much lower overall identity to papain (30%) or other cathepsin L-like proteases. The sequence identity of the L. major cpB (Sakanari et al. 1997) to the L. mexicana cpB, (Bart et al. 1995) is 80% consistent with the close relationship of these two species.
A biochemical property of cathepsin B-like proteases is their ability to cleave synthetic substrates with Arg in position P 2 (e.g., Z-Arg-Arg-AMC). Cathepsin L-like proteases have a stricter preference for substrates with a Phe in position P 2 (e.g., Z-Phe-Arg-AMC) (Khouri et al. 1991; Storer and Menard 1996) . In the assay system used in this study bovine spleen cathepsin B cleaves both substrates at about the same rate, whereas papain has about 10% activity toward Z-Arg-Arg-AMC compared to 100% toward Z-Phe-Arg-AMC (data not shown). This is consistent with previous data indicating that cathepsin B prefers Phe over Arg in position P 2 only 3.6-fold while papain favors it by a factor of 904 (Storer and Menard 1996) . Glutamic acid 205 (papain numbering, Table I ) is responsible for the ability to cleave substrates with an Arg in position P 2 . In a double mutant of papain (Val 133 → Ala/Ser 205 → Glu), exchanging serine 205 for glutamic acid by site-directed mutagenesis enhanced the ability of papain to cleave Z-Arg-Arg-AMC substrates by about 100-fold (Khouri et al. 1991) . Recently the crystal structure of cathepsin B and a peptide inhibitor with an Arg in position P 2 finally proved this theory (Jia et al. 1995) . Position 205 is also a glutamic acid in cruzain which has the ability to cleave Z-Arg-Arg-AMC but still prefers Z-Phe-Arg-AMC at acidic pH (data not shown). L. major cpB shows no activity toward Z-Arg-Arg-AMC but is active against Z-PheArg-AMC. Its counterpart from L. mexicana prefers Phe over Arg in Position P 2 but still shows 10% activity toward Z-Arg-Arg-AMC (Robertson and Coombs 1993) . This difference in the substrate specificity is reflected in position 205. The L. mexicana cpB has a serine, like papain, at this position, whereas L. major cpB has a glycine ( Table I) . Replacement of glutamic acid 205 by a glycine in L. major cpB results in the S2 site having a much larger and more hydrophobic pocket (Fig. 1, Fig. 2) . Thus, while L. major cpB belongs to the cathepsin B subfamily by virtue of its structural homology, its activity is more ''cathepsin L-like''. This observation confirms that there is a need for analyzing sequence, structure, and enzymatic data before concluding an enzyme is a member of a specific protease subfamily. It also underscores the potential functional diversity of the cathepsin B proteases as evidenced by the ability to significantly alter substrate specificity by a single residue change in S2.
The structural models of the L. major cpB and cpL were used to search the ACD for potential protease inhibitors. ACD is a database of about 150,000 commercially available compounds formerly known as the Fine Chemicals Directory distributed by Molecular Design Limited Information System (San Leandro, CA). This approach was performed with the software DOCK3.5 (University of California, San Francisco) (Kuntz 1992; Kuntz et al. 1994) . The computational software DOCK3.5 is a suite of programs for locating feasible binding orientations, given the structure of a ligand molecule and a receptor molecule. In SEARCH mode, orientations are generated for each of the scoring molecules in a database, then the bestscoring orientation of each molecule is saved, and the best-scoring molecules are saved to a file. Two scoring lists were generated, a contact score and a force field interaction energy score. The top 3% for each scoring method was saved and visually examined for size, packing, and interactions within the active site. In order to find new lead inhibitors, the most promising compounds (about 0.05%) were selected to be tested in vitro. Out of 150,000 compounds 4500 were saved for each scoring method (force field and contact score). Following visual examination of fit, 69 compounds were finally selected for testing. Of these 69 compounds, 43 were from the contact list, 26 were from the force field list, and 15 compounds appeared on both lists. Forty-five of the 69 cpB compounds also appeared within the top 3% lists (contact and force field score) from the L. major cpL screen.
Because the L. major cpB is available in reagent quantities it was chosen for biochemical screens. Eighteen of the chosen compounds showed an IC 50 between 50 and 100 M and 3 (PS44, reactive orange, 16, 2-((4-(7-acetamido-1-hydroxy-3-sulfo-2-naphthylazo)phenyl)sulfonyl)-ethyl sulfate, contact list; PS50, succinimidyl 4-(p-maleimidophenyl)butyrate, both lists; PS28, 3,5 dichlorofolic acid, L-glutamic acid, N-[4[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl] )methyl]amino]-3,5-dichlorobenzoyl, both lists) showed an IC 50 below 50 M (Table  II, Fig. 3) . Thirteen of the 18 compounds including PS28, PS44, and PS50 were also found on the lists for the L. major cpL. PS50 is likely an irreversible inactivator of the protease. Its maleimide group binds specifically to free sulfur groups (Smyth et al. 1964 ). In L. major cpB the highly reactive sulfur in the cysteine of the catalytic triad is a likely target. This would lead to a covalent bond between the maleimide group and the L. major cpB active site. Indeed inhibition by PS50 could not be competed by excess amounts of substrate consistent with irreversible inhibition. PS44 contains three sulfate groups which make it a highly negatively charged compound and difficult to derivatize. Most likely these hydrophilic groups are responsible for the inhibitory activity. However, since the S-subsites of the target proteases are rather hydrophobic, PS44 was not further considered as a lead compound.
The most promising lead compound is PS28. PS28 is a derivative of folic acid and therefore belongs to a well-studied group of compounds, some of which are drugs. Dihydrofolic acid is a substrate of the dihydrofolic acid reductase (DHFR), itself a drug target (Schweitzer et al. 1990 ). Methotrexate and aminopterin, used in anticancer treatment, are highly active inhibitors of DHFR (Schweitzer et al. 1990 ). These latter 2 compounds were among the 18 compounds showing IC 50 's between 50 and 100 M. While PS28 was a byproduct of anticancer drug development (Martinelli and Chaykovsky 1980) , until now no enzyme inhibition activity, or biological activity, had been reported for this compound.
The three-dimensional structure of PS28 was modeled with Sybyl and docked into the active site of L. major cpB by using the SINGLE mode function of DOCK3.5. In SINGLE mode DOCK3.5 generates many orientations of one ligand for both contact scoring and force field scoring. These orientations can be examined for interactions of the ligand and its receptor to determine the most likely orientation. A high percentage of the orientations (contact and force field score) generated by DOCK3.5 for PS28 and L. major cpB showed the pteroic acid half Note. Inhibitory activity of first (PS)-and secondgeneration compounds (ZL) toward different cysteine proteases. Note differences in activity of parasite versus nonparasite proteases from 2-to 100-fold. IC 50 determined from plot of five or more assays at specific inhibitor concentrations. of the compound close to the catalytic triad and the SЈ-site and at least one of the chlorides would interact with the catalytic triad (Fig. 2) . The hydrophilic glutamic acid was predicted as pointing into either the hydrophobic S 1 -site or the wide open hydrophobic S 2 -site, both unfavored interactions. This suggests that compounds having a more hydrophobic moiety may be better inhibitors. The synthesis of such chemical derivatives is now a goal of our project. The carboxylic acids of the glutamic acid will be eliminated, and the glutamic acid will be replaced by phenylalanine or homophenylalanine.
A second approach to inhibitor discovery and design for the L. major cysteine proteases was to test a library of compounds, synthesized by combinatorial chemistry, and based on an original lead compound [oxalic bis(2-hydroxy-1-naphthylmethylene)hydrazide] found by DOCK using the malaria cysteine protease falcipain as a target (Ring et al. 1993) . Of special note is the fact that the hydrazide lead was also among the compounds selected by computer search of ACD for the L. major cpB and cpL. From this lead a second generation of compounds had been synthesized (ZL-compounds, Fig. 3 ) and tested against falcipain as well as against the malaria parasite in cell culture. Some of these compounds proved to be potent inhibitors of both the protease and parasite growth in culture (Li et al. 1994 (Li et al. , 1995 (Li et al. , 1996 . Although the overall sequence identity of falcipain and the L. major cpB is only 31%, key regions of substrate binding are conserved and several of these inhibitors had IC 50 's in the nanomolar range versus the L. major cpB (Table II) . The enhanced inhibitory activity of these second-generation compounds is the result of specific synthetic modifications based on computer predictions made with DOCK. For the L. major cpB, these results again emphasize that while its overall homology is to cathepsin B, it shares substratebinding similarities with cathepsin L-like enzymes like falcipain.
The three hydrazides (ZLIII43A, ZLIII115A, and ZLIII133A) were also tested in L. major cell cultures. Inhibitors were added to replicating promastigotes (10 6 cells ml −1 ) as a single dose and cell growth was monitored over 3 days. All three compounds showed very similar effects on the replication rate of the parasite. Concentrations of 5 M led to about half maximal growth whereas 20 and 50 M totally inhibited cell growth (Fig. 4) . Exchanging the media every day for a total of 3 days, thereby keep- ing inhibitor concentrations stable (20 and 50 M), led to death of all the parasites. After the fourth day the media was exchanged with fresh media without inhibitor and the flasks were kept under culture conditions. Even after 10 days no parasites could be detected, indicating a total cure of the Leishmania culture by the cysteine protease inhibitors. ZLIII43A and ZLIII115A at 40 M had no effect on the growth or appearance of J774 cells, a mammalian macrophage cell line. Evaluation of these compounds on intracellular L. major amastigotes and in mice will be reported in another paper (Selzer, Pingel, Hsieh, Chan, Engel, Sakanari, and McKerrow, submitted for publication).
The results of these cell culture assays suggest that the cysteine proteases of L. major are crucial to the parasite. Mottram and co-workers reported that a cpL null mutant of L. mexicana showed an 80% decrease in virulence but was still able to grow . L. mexicana has multiple cysteine proteases of both the cpL and cpB type (Robertson et al. 1996) . Since the inhibitors we tested inhibit both cpLs and cpBs, they may target both types of proteases within the parasite, overcoming the redundancy in activity suggested by the null mutant studies. Because the inhibitors are reversible, it was not possible to identify specific protease targets by inhibitor labeling. The lack of toxicity to mammalian cells at the inhibitor concentrations which kill parasites may reflect a greater protease redundancy in mammalian lysosomes (Mason 1991; Kirschke et al. 1995) or differential uptake of inhibitor by parasites versus host cells (McGrath et al. 1995) .
